US Penny Stocks To Consider In November 2024

As of late November 2024, the U.S. stock market has been experiencing a strong upswing, with the Dow Jones Industrial Average closing at record highs and major indices posting weekly gains. For those interested in exploring opportunities within smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing investment area. When backed by solid financials, these stocks can offer potential value and growth that might not be as readily found in larger firms. In this article, we highlight several penny stocks that stand out for their financial strength and potential for long-term success.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.83945	$6.1M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$143.12M	★★★★★★
RLX Technology (NYSE:RLX)	$1.80	$2.29B	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.233	$8.57M	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$3.39	$557.36M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.55	$51.15M	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8899	$80.04M	★★★★★☆
Information Services Group (NasdaqGM:III)	$3.11	$173.23M	★★★★☆☆

Click here to see the full list of 733 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Gevo (NasdaqCM:GEVO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Gevo, Inc. operates as a carbon abatement company with a market cap of approximately $367.59 million.

Operations: The company's revenue is primarily derived from its Renewable Natural Gas segment, which generated $14.63 million, while the Gevo segment contributed $0.96 million.

Market Cap: $367.59M

Gevo, Inc., with a market cap of approximately US$367.59 million, is navigating challenges typical for penny stocks. Despite having more cash than total debt and sufficient short-term assets to cover liabilities, the company remains unprofitable with increasing losses over the past five years. Recent earnings show decreased sales and a widening net loss. Gevo's stock price volatility has increased, and it faces Nasdaq delisting risks due to its sub-$1 share price but plans potential measures like a reverse stock split to regain compliance. A recent executive change may also impact financial strategies moving forward.

• Jump into the full analysis health report here for a deeper understanding of Gevo.
• Review our growth performance report to gain insights into Gevo's future.

AbCellera Biologics (NasdaqGS:ABCL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AbCellera Biologics Inc. is focused on creating an engine for antibody drug discovery and development, with a market cap of approximately $815.21 million.

Operations: The company generates revenue primarily from the discovery and development of antibodies, amounting to $32.96 million.

Market Cap: $815.21M

AbCellera Biologics, with a market cap of US$815.21 million, exemplifies the volatility and potential of penny stocks. Despite being debt-free and having experienced management and board teams, the company is unprofitable with increasing losses over recent years. Revenue for the third quarter was US$6.51 million, slightly down from last year, while net loss widened to US$51.11 million from US$28.61 million previously. The company's short-term assets significantly exceed liabilities, providing some financial stability amidst challenges in profitability and declining earnings forecasts over the next three years by 10.7% annually on average.

• Click here and access our complete financial health analysis report to understand the dynamics of AbCellera Biologics.
• Assess AbCellera Biologics' future earnings estimates with our detailed growth reports.

GoodRx Holdings (NasdaqGS:GDRX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: GoodRx Holdings, Inc. provides tools and information for consumers to compare prescription drug prices and save money in the United States, with a market cap of approximately $1.89 billion.

Operations: The company's revenue is primarily derived from its Healthcare Software segment, which generated $790.39 million.

Market Cap: $1.89B

GoodRx Holdings, with a market cap of US$1.89 billion, showcases the complexities of penny stocks through its evolving financial landscape. Despite being unprofitable, it has improved its financial position by maintaining a positive free cash flow and reducing debt over time. Recent initiatives include partnerships to enhance affordability for medications and an e-commerce rollout to expand consumer access to health products. The company reported third-quarter revenue of US$195.25 million and net income of US$3.97 million, marking a turnaround from previous losses. Its short-term assets comfortably cover liabilities, indicating robust liquidity amidst ongoing strategic shifts.

• Click to explore a detailed breakdown of our findings in GoodRx Holdings' financial health report.
• Learn about GoodRx Holdings' future growth trajectory here.

Seize The Opportunity

• Jump into our full catalog of 733 US Penny Stocks here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com